Vaccine: Berlin protects one of its labs appetite foreign

Vaccin: Berlin protège un de ses laboratoires d’appétits étrangers

The German State will become a shareholder of the German biopharmaceutical CureVac, well placed in the race toward a vaccine against the coronavirus, to prevent its purchase by a foreign investor, and especially american.

The public bank German KfW development, the financial arm of the State, will invest 300 million euros to acquire a 23% equity interest in the firm of biotechnologies Tübingen, said on Monday the ministry of Economy.

“The decision of participation must ensure that the company is not acquired by a foreign investor” after its ipo “in New York scheduled for July 2020,” explains the ministry in a note to German mps in the Bundestag, quoted by the newspaper Die Welt.

“It is in the interest of the State that a supply of basic vaccine is guaranteed to the population in Germany”, adds the document.

To date, CureVac is owned 80% by the funds Dievini, itself controlled by Dietmar Hopp, German billionaire founder of the giant software packages SAP.

The technology of CureVac, based on molecules known under the name of”messenger RNA” (Mrna) and which are located in the body, offers “excellent potential for vaccines against the COVID-19, but also of many other infectious diseases, as well as therapeutic options for many other indications,” said Mr. Hopp in a video.

Germany expects from its investment that it “accelerates the development” of CureVac for a vaccine produced in quantity, said the Economics minister, Peter Altmaier, who is quoted in the press release.

In march, the German government had to intervene to stop in extremis attempts, led by the White House, of redemption, of the firm of Tübingen.

Berlin had subsequently strengthened its legislative framework to protect strategic sectors, including the medical, of appetite foreign.

The investment in CureVac occurs after the agreement announced Saturday by several countries of the european Union, including Germany and France, to secure the supply of vaccines against the novel coronavirus, the pharmaceutical group AstraZeneca guaranteeing the delivery of up to 400 million doses.

Share Button